Sporadic and endemic Burkitt lymphoma have frequent <em>FOXO1</em> mutations but distinct hotspots in the AKT recognition motif by Zhou P et al.
GLOBAL ADVANCES
Sporadic and endemic Burkitt lymphoma have frequent FOXO1mutations
but distinct hotspots in the AKT recognition motif
Peixun Zhou,1 Alex E. Blain,1 Alexander M. Newman,1 Masood Zaka,1 George Chagaluka,2 Filbert R. Adlar,1 Ugonna T. Offor,1,3
Casey Broadbent,1 Lewis Chaytor,1 AmberWhitehead,1 Amy Hall,1 Hettie O’Connor,1 Susan Van Noorden,4 Irvin Lampert,5 Simon Bailey,1,3
Elizabeth Molyneux,2 Chris M. Bacon,1,6 Simon Bomken,1,3 and Vikki Rand1
1Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom; 2Department of
Paediatrics, College of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi; 3Department of Paediatric and Adolescent Haematology and Oncology, The Great North
Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; 4Department of Histopathology, Imperial College London,
Hammersmith Hospital, London, United Kingdom; 5Department of Histopathology, West Middlesex University Hospital, Isleworth, United Kingdom; and 6Department of Cellular
Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Key Points
• FOXO1 mutations oc-
cur in 1/3 of sporadic
and 1/2 endemic pedi-
atric BL cases and
cluster in and adjacent
to the AKT
recognition motif.
• FOXO1 mutations oc-
cur in the major clone at
initial diagnosis and are
retained at relapse but
are not associated with
outcome.
FOXO1 has an oncogenic role in adult germinal center–derived lymphomas, in which
mutations, predominately within the AKT recognition motif, cause nuclear retention of
FOXO1, resulting in increased cell proliferation. To determine the prevalence and
distribution of FOXO1 mutations in pediatric Burkitt lymphoma (BL), we sequenced
a large number of sporadic and endemic BL patient samples. We report a high frequency of
FOXO1 mutations in both sporadic and endemic BL at diagnosis, occurring in 23/78 (29%)
and 48/89 (54%) samples, respectively, as well as 8/16 (50%) cases at relapse. Mutations of
T24 were the most common in sporadic BL but were rare in endemic cases, in which
mutations of residue S22, also within the AKT recognition motif, were the most frequent.
FOXO1 mutations were almost always present in the major tumor cell clone but were not
associated with outcome. Analysis of other recurrent mutations reported in BL revealed
that FOXO1mutations were associated with mutations of DDX3X and ARID1A, but notMYC,
TCF3/ID3, or members of the phosphatidylinositol 3-kinase signaling pathway. We further
show common nuclear retention of the FOXO1 protein, irrespective of mutation status,
suggesting alternative unknown mechanisms for maintaining FOXO1 transcriptional
activity in BL. CRISPR/Cas9 knockout of FOXO1 in an endemic cell line produced a significant
decrease in cell proliferation, supporting an oncogenic role for FOXO1 in endemic BL.
Thus, FOXO1 is frequently mutated in both sporadic and endemic BL and may offer
a potential therapeutic target for pediatric BL patients worldwide.
Introduction
The forkhead box subtype O (FOXO) family of transcription factors have pleiotropic roles in development
and immunity and context-dependent tumor suppressor and oncogenic capacity.1-3 During the germinal
center reaction, FOXO1 controls B-cell trafficking through cycles of clonal expansion and affinity
maturation.4,5 Within the normal germinal center, nuclear FOXO1 directs a gene expression program in
the dark zone, in which B cells proliferate and undergo immunoglobulin somatic hypermutation, but
FOXO1 activity is downregulated by phosphatidylinositol 3-kinase (PI3K) signaling in the light zone,
where cells undergo affinity selection and further differentiation. Here, B-cell receptor (BCR) signaling
through the PI3K cascade causes AKT-dependent phosphorylation of the T24 residue of FOXO1,
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resulting in sequestration by 14-3-3 in the cytoplasm, nuclear
exclusion, and loss of transcriptional activity.6,7 Thus, FOXO1 and
BCR/PI3K work in opposition as regulators of the germinal center
reaction.
Given the critical role of BCR/PI3K signaling in the pathogen-
esis of germinal center–derived lymphomas8 such as Burkitt
lymphoma (BL) and diffuse large B-cell lymphomas (DLBCL),9,10
the occurrence of FOXO1 mutations in these malignancies is of
great interest. FOXO1 mutations have been identified in up to 11%
of adult DLBCL,11-18 and FOXO1 has been identified as a driver
gene in DLBCL cell lines.15 DLBCL with mutations of the M1
residue, resulting in loss of the AKT recognition motif, or within
this motif itself, have aberrant nuclear localization of FOXO1 and
are associated with a poorer prognosis.17 Activating FOXO1
mutations have also been identified in tumors from a murine MYC/
PI3K-driven model of BL and in human BL cell lines.19 These
models demonstrate the role of T24 mutations in uncoupling
FOXO1 from BCR/PI3K, driving nuclear localization of FOXO1
protein with subsequent pro-proliferative and pro-survival effects.
However, to date, next-generation sequencing (NGS) based
studies have identified FOXO1 mutations in only a small proportion
of BL patient samples,20-24 raising the question of how FOXO1
functions in the setting of BCR/PI3K signaling in BL.
We report a comprehensive analysis of FOXO1 mutations in the
largest cohort of pediatric sporadic and endemic BL patient
samples sequenced to date. We show a high frequency of FOXO1
mutations in pediatric sporadic and endemic BL, revealing different
mutation hotspots within the AKT recognition motif in the 2 BL
subtypes. We show nuclear localization of FOXO1 in patient
samples and cell lines and provide functional knockout data
supporting an important role for FOXO1 as an oncogenic factor
in the pathogenesis of BL.
Methods
Patient samples and cell lines
Sporadic BL samples from UK hospitals were deposited in the
Children’s Cancer and Leukaemia Group (CCLG) Tissue Bank
between 1995 and 2014. Project approval was obtained from the
CCLG Biological Studies Steering Group (2012 BS 08). CCLG
samples were stored either frozen or following formalin fixation and
paraffin embedding. Endemic BL samples were collected at Queen
Elizabeth Central Hospital, Blantyre, Malawi, between 2009 and
2016, with ethical approval from the College of Medicine Research
and Ethics Committee (Malawi). Surplus material from fine-needle
aspirates was fixed in ThinPrep PreservCyt Solution (Hologic,
Manchester, United Kingdom) and stored at ambient temperature.
For both sporadic and endemic BL, diagnoses were confirmed by
pathology review according to World Health Organization criteria
using immunocytochemistry (including CD20, CD3, CD10, BCL2,
BCL6, and Ki67), in situ hybridization for Epstein-Barr virus–
encoded small RNA and fluorescence in situ hybridization for MYC
translocations.25 Sporadic BL patients were treated according
to French-American-British/Lymphome Mains de Burkitt–based
protocols,26-28 and endemic BL patients were treated with low-
intensity therapy based on a published 28-day regimen29,30
(Table 1).
To generate patient-derived xenograft models, diagnostic patient
samples were retrieved from the Newcastle Biobank and transplanted
Table 1. Clinical and molecular characteristics of BL cohorts
Sporadic BL Endemic BL
Total cases, n 78 89
Median age at diagnosis (range), y 8 (0-19) 7 (2-16)
Sex, n (%)
Male 61 (78.2) 57 (64.0)
U 5 (6.4) 1 (1.1)
Tumor stage, n (%)
High (3 or 4) 30 (38.5) 58 (65.2)
U 38 (48.7) 8 (9.0)
CSF involvement, n (%)
Y 1 (1.3) 10 (11.2)
U 28 (36.0) 25 (28.1)
BM involvement, n (%)
Y 18 (23.1) 8 (9.0)
U 17 (21.8) 33 (37.1)
CNS involvement, n (%)
Y 4 (5.1) ND
U 23 (29.5)
EBV positive, n (%)
Y 4 (5.1) 76 (85.4)
U 22 (28.2) 13 (14.6)
MYC translocation, n (%)
Y 73 (93.6) 89 (100)
U 1 (1.3) 0 (0)
Treatment, n (%)
FAB/LMB 96 Protocol 63 (81) —
Group A 1 —
Group B 44 —
Group C 14 —
Group unknown 4 —
Malawi 28 d protocol* — 78 (88)
With doxorubicin — 60
Reduced protocol — 18
No treatment 1 (1) 5 (6)
U 14 (18) 6 (7)
Follow-up
Number of cases with follow-up data (%) 71 (91.0) 71 (79.8)
Disease progression
Relapse/refractory disease, n 10 22
Median time to relapse (range), mo 5.5 (2.8-6.7) 5.1 (1.6-10.9)
DFS
Progression or death from lymphoma, n 12 30
Median time to event (range), mo 4.83 (0.9-6.7) 3.92 (0.03-10.9)
OS
Dead, n 12 31
Median time to death (range), mo 4.42 (0.1-11.1) 4.73 (0.03-14.6)
BM, bone marrow; CNS, central nervous system; CSF, cerebrospinal fluid; EBV, Epstein-Barr
virus; FAB-LMB, French-American-British/Lymphome Mains de Burkitt; U, unknown; Y, yes.
*Endemic BL patients were treated with low-intensity 28-d regimen,29,30 receiving
cyclophosphamide (cyclo), vincristine (vcr), prednisolone (pred), and doxorubicin (dox).
Eighteen endemic BL patients received a reduced protocol (4 had cyclo only, 6 cyclo1vcr,
and 8 cyclo1vcr1pred).
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into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice in accordance with the
Biobank’s ethical approval (NRES Committee, 16/NE/0002)
and the Home Office project license PPL 60/4552. Resultant
tumors were harvested and mechanically disaggregated to
provide single-cell suspensions. BL cell lines were purchased
from DSMZ (Germany) and cultured in Gibco RPMI 1640 medium
with 10% fetal bovine serum (Fisher Scientific, Loughborough,
United Kingdom).
Sanger sequencing
DNA and RNA were extracted using Qiagen Allprep Kit. Primers
were designed to amplify the coding region of the FOXO1 transcript
ENST00000379561 (supplemental Table 1). The expression of
mutant alleles in cell lines was confirmed by reverse transcriptase
polymerase chain reaction (PCR) using the High Capacity RNA-to-
cDNA Kit (Fisher Scientific). DNA was amplified using the Repli-g
Kits (Qiagen, Manchester, United Kingdom) for cases with small
samples and low DNA yields. PCR products were amplified using
the AmpliTaq Gold DNA Polymerase kit (Fisher Scientific) and
amplification of the GC-rich exon 1 was enhanced by addition of
5% v/v dimethyl sulfoxide and 0.8M betaine solution (Sigma-Aldrich,
Gillingham, United Kingdom).17 PCR products were amplified using
the SureCycler 8800 (Agilent, Cheshire, United Kingdom) and then
purified using the QIAquick PCR Purification Kit (Qiagen) and
sequenced by Eurofins Genomics (Ebersberg, Germany).
ABI format files were analyzed using GeneScreen and visualized
using FinchTV software (Geospiza).31 Heterozygous mutation calls
required a .0.2 peak height ratio and all mutated bases had
a quality score.0. Each ABI chromatogram was manually checked
to ensure the absence of background noise, “dye blobs,” low signal,
or discordant mutation calls between forward and reverse reads.
Any conflicts or poor-quality reads were resequenced to remove
potential false positives. The high GC content of exon 1 proved
challenging when designing nested PCR primers for both the
forward and reverse for 2 regions; therefore, 3 mutations in endemic
(S205T, S206L, A207P) and 2 in sporadic BL (both D82N) could
be identified in 1 direction only. In 14 sporadic and 8 endemic
BL cases, the FOXO1 mutations were shown to be somatic
nonsynonymous mutations by sequencing matched constitutional
DNA. Where constitutional DNA was unavailable, mutations were
analyzed against the Catalogue of Somatic Mutations in Cancer,
the Single Nucleotide Polymorphism database, and the Exome
Aggregation Consortium database to remove germline variants.
Next-generation sequencing and mutation
data analysis
Whole-exome sequencing (WES) data were generated for 74
sporadic BL samples using Illumina Nextera Exome enrichment by
the Newcastle University Genomics Core Facility. Because of the
low yields and poor quality of DNA from fine-needle aspirates, WES
data could not be generated for the endemic BL cohort. Data were
analyzed using Genome Analysis Toolkit32,33 and aligned using
BWA-MEM. Aligned SAM files were sorted, converted to BAM,
indexed, and PCR duplicates marked using Picard. Variants were
called using MuTect.34 Matched constitutional DNA was used
to call variants where available. For cases with no matched DNA, a
pool of 33 constitutional DNAs from B-cell non-Hodgkin lymphoma
patients with no other underlying conditions was used as the
reference. Variants were annotated with gene and gene function
data from Ensembl’s Variant Effect Predictor. Data were visualized
in Integrative Genomics Viewer.35 Comparative genomic analysis to
determine the conservation of residues within the AKT recognition
motif was performed. FOXO1 protein sequences forHomo sapiens
and 10 other species were downloaded from the Uniprot database
and aligned using MUSCLE software.36 Alignments were visualized
with Jalview software.37
FOXO1 mutations in BL samples were identified in the supplemen-
tary files of 5 published studies.20-24 To investigate the coverage of
the FOXO1 gene, raw FASTQ files were downloaded from dbGAP
and analyzed as described above. FOXO1mutations and sequence
coverage were visualized in Integrative Genomics Viewer.
Data are available from the European Genome-phenome Archive
accession number EGAS00001003719.
Survival analysis
Estimates of overall survival (OS) and disease-free survival (DFS)
were calculated and compared using Kaplan-Meier methods, log-
rank tests, and univariate Cox regression models. For both
sporadic and endemic BL, OS was defined as the time from
diagnosis to death from any cause, with censoring at the date of
last contact. DFS was calculated from the date of diagnosis to
relapse or death from lymphoma, censoring deaths from other
causes. Factors present were considered to be significant when
P , .05. All variables conformed to the proportional hazards
assumption. Other comparisons were performed using the
Fisher’s exact test. Analyses were performed using R Bioconduc-
tor packages “survival” for univariate analysis and “survminer” for
visualization of Kaplan-Meier survival curves, using modified in-
house R scripts.
FOXO1 knockout by CRISPR/Cas9 gene editing
CRISPR/Cas9 single guide sequences specifically targeting
FOXO1 (sgFOXO1) were designed using the CHOPCHOPv2
Web tool and cloned into the lentiCRISPRv2 plasmid. The plasmid
was a kind gift from Fen Zhang (Addgene plasmid #52961; http://
n2t.net/addgene:52961; RRID:Addgene_52961).38 The nontar-
geting control sequence used was 59-TGAGGATCATGTCGA
GCGCC obtained from the GeCKOv2 library (Addgene). Lentiviral
particles were produced in 293T cells and concentrated by
ultracentrifugation. BL cell lines were transduced with sgFOXO1
lentiviruses or nontargeting control and puromycin (Santa Cruz
Biotechnology, Dallas, TX) was added on day 4, using the minimal
toxic dose per cell line to select transduced cells. Lentiviral trans-
duction efficiency was established on day 6 by measuring the
percentage of viable cells selected by puromycin relative to
nonselected control cells. Viral titers with transduction efficiencies
of ,40% were used to avoid excessive multiple viral integrations.
Single colonies for Jiyoye and Ramos were selected by methylcel-
lulose colony formation assay and limiting dilution assay, respec-
tively. The effect of FOXO1 gene editing on cell proliferation was
assessed by Trypan Blue viable cell counting over a 7-day time
course, and for apoptosis by flow cytometry (BD FACSCalibur)
using Annexin V/7-AAD (BD Biosciences). For each cell line, 3
independent experiments were performed for both the bulk and
clonal populations. The GraphPad Prism 6 software (GraphPad
Software, USA) was used for 2-tailed unpaired Student t test, as
well as plotting histograms and scatter plots. Statistical signif-
icance was considered as P , .05. Total protein from BL cells
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was extracted using Pierce RIPA buffer (Fisher Scientific) and
cytoplasmic and nuclear protein was extracted with the NE-PER
Nuclear and Cytoplasmic Extraction Kit (Fisher Scientific). Protein
expression was determined by western blotting probed for FOXO1
(Cell Signaling, 2880S), PARP (9542S; Cell Signaling) or a-Tubulin
(T6199; Sigma-Aldrich) with Amersham ECL detection (GE
Healthcare Life Sciences, Buckinghamshire, United Kingdom).
Results
Clinical and molecular characteristics of the sporadic
and endemic BL cohorts
Diagnostic samples taken at first presentation were obtained
from 78 patients with sporadic BL and 89 patients with endemic
BL. The clinical and molecular characteristics of these cohorts
are summarized in Table 1. The median follow-up for sporadic BL
was 49.4 (0.1-228.6) months and for endemic BL was 12.1
(0.03-45.6) months. Survival estimates at 12 months for OS and
DFS were 83.1% (95% confidence interval [CI]. 74.8-92.3) and
82.4% (95% CI, 73.8-92.0), respectively, for the sporadic BL
and 70.5% (95% CI, 60.0-82.7) and 54.4% (95% CI, 43.6-68.0),
respectively, for endemic BL. The median survival time was
not reached in either cohort. For those sporadic and endemic
BL patients who had progressive disease (relapse or primary
refractory disease), the median time from initial diagnosis to
progression was 5.5 and 5.1 months, respectively. We found
MYC rearrangements in 73 of 78 (94%) sporadic BL. Sixty-nine
sporadic BL cases had an IG-MYC translocation, 4 had a MYC
translocation but the partner was unconfirmed, 1 failed fluores-
cence in situ hybridization, and 4 had no detectable MYC trans-
location. All endemic BL cases (89/89; 100%) carried an IG-MYC
rearrangement. Tumor EBV status was determined by Epstein-
Barr virus–encoded small RNA in situ hybridization. EBV status
was available for 56 and 76 sporadic and endemic BL samples,
respectively, with 4/56 (7.1%) sporadic and all 76/76 (100%)
endemic BL cases EBV positive.
FOXO1mutations occur at high frequency in sporadic
and endemic BL
Using Sanger sequencing, we identified 27 FOXO1 mutations in
23/78 (29%) sporadic BL samples, and 59 mutations in 48/89
(54%) endemic BL samples taken at first diagnosis (Figure 1A-B;
supplemental Tables 2 and 3). Of the 86 mutations, 83 were
missense mutations with only 1 M1 mutation and 2 Q133* nonsense
mutations detected. The frequency of mutations contrasts strikingly
with the substantially lower frequencies previously reported using
NGS approaches: 4/86 (5%) sporadic BL and 2/48 (4%) endemic
BL (supplemental Figure 1; supplemental Table 4).20-24 To confirm
the observed FOXO1 mutational status, we analyzed WES data for
74/78 sporadic samples. This included 21 of the 23 mutated
cases, in which a total of 25 FOXO1 mutations had been
identified by Sanger sequencing. WES confirmed 21/25 (84%)
of those mutations (examples shown in supplemental Figure 2).
WES analysis highlighted poor coverage of the GC-rich exon 1
compared with exon 2 and all 4 mutations (D82N in 2 samples,
H119Y and P138S) not confirmed by WES were located
within a region of exon 1 with no or virtually no read coverage
(supplemental Figure 3). No additional FOXO1 mutations were
detected in any of the 74 cases analyzed by WES.
Sporadic and endemic BL have different mutation
hotspots within the AKT recognition motif
The majority of recurrent FOXO1 mutations clustered within or
close to the AKT recognition motif (RxRxxS/T) at amino acid
residues 19 through 24 (Figure 1A-C), implying a role in aberrant
nuclear localization of FOXO1. Overall, 23 and 26 FOXO1mutations
were identified involving the evolutionarily conserved cluster region
between residues R19 and L27 and the M1 residue in 20 of 78
sporadic and 25 of 89 endemic BL samples obtained at diagnosis,
respectively (supplemental Figure 4). Despite their similar combined
frequencies, the distribution of mutations within this cluster region
differed between subtypes. Mutations of the T24 phosphorylation
site were the most common mutation in sporadic BL, representing
10/23 (37%) mutations within the cluster region. Strikingly, only
2/26 (8%) mutations in the cluster region of endemic BL cases
involved T24, whereas mutations of S22 were instead the most
common, being seen in 8/26 (31%) samples. Mutations were also
identified distal to the AKT recognition motif. Most commonly these
were nonrecurrent mutations in endemic BL, but we also identified
previously unreported recurrent mutations at P122, Q133, and
G586 in endemic BL and D82 in sporadic BL. These mutations
were predominantly located in exon 1, but most were outside the
DNA binding domain and their functional relevance remains unclear.
Mutations in ARID1A and DDX3X are associated with
FOXO1 mutations
Wenext sought to determine, in our sporadic BL cohort, the relationship
between FOXO1 mutations and additional mutations previously
reported to be recurrent in BL. In keeping with previous reports, the
most commonly mutated genes wereMYC, ID3, and TP53 occurring
in 47/74 (64%), 44/74 (59%), and 37/74 (50%) cases, respectively
(Figure 2). Among themutations examined, mutations in 2 geneswere
associated with FOXO1 mutations: DDX3X (present in 8/21 FOXO1
mutated vs 7/53 FOXO1 nonmutated cases, P 5 .025) and ARID1A
(present in 9/21 FOXO1 mutated vs 8/53 FOXO1 nonmutated cases,
P5 .016). Six of the 15 DDX3X mutations were nonsense mutations,
the remaining 9 were missense mutations, and all but 1 were located in
either the DEAD box helicase domain or the Helicase C terminus
supplemental Figure 5A). Eighteen ARID1A mutations were detected
in 17 cases, including 3 frameshift mutations, 10 nonsense mutations,
and 5 missense mutations (supplemental Figure 5B). These mutations
were distributed equally throughout the ARID1A protein.
To determine whether FOXO1mutations were present in the dominant
tumor cell clone we compared the variant allele frequencies of
FOXO1 point mutations with those of other mutations present in the
same samples (supplemental Table 5). Eighteen sporadic samples
contained FOXO1 mutations detected by WES, and in almost all of
these (16/18; 89%), the FOXO1mutations were present in the major
clone. In only 2 cases, the variant allele frequencies of the FOXO1
mutations were substantially lower than those of other mutations,
suggesting that they were present within a sub-clonal population.
FOXO1mutations are not associated with outcome in
BL subtypes but are retained at relapse
Given a reported association between FOXO1 mutations and a poor
outcome in DLBCL,17 we assessed the association between FOXO1
mutation status and prognosis in both the sporadic and endemic BL
cohorts. We found that neither OS nor DFS was associated with
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FOXO1 mutation status in either BL subtype (Figure 3). We also
investigated the prognostic significance of mutations within the AKT
binding motif (R19-T24) and the extended evolutionarily conserved
cluster region (M1 and R19-L27), in which mutations have been
predicted to result in persistent FOXO1 transcriptional activity.
However, there was no association with outcome in our cohorts
(supplemental Table 6).
To further determine whether FOXO1 mutations might be associ-
ated with disease progression, we sequenced FOXO1 in 5 sporadic
and 11 endemic BL samples obtained at the time of disease relapse.
FOXO1 mutations were detected in relapse samples at frequencies
similar to those seen at presentation: 2/5 (40%) sporadic and 6/11
(55%) endemic BL relapse samples (supplemental Figure 6). Overall,
9 mutations were detected, of which 6 were located within or
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juxtaposed to the AKT recognition motif. Four matched diagnostic
and relapse samples were concordant for FOXO1 mutations:
2 patients, 1 sporadic and 1 endemic BL, had FOXO1 mutations
(R21H and P26L) and 2 were unmutated at both initial diagnosis
and relapse. WES data were not available for the 2 mutated cases,
so quantitative analysis of allele frequency could not be performed.
CRISPR/Cas9 knockout supports an oncogenic role
of FOXO1 in endemic BL
The demonstration of FOXO1 mutations in a high proportion of BL
samples, the presence of these mutations in the dominant tumor
cell clone in most cases, and the clustering of mutations in or
around the AKT recognition motif suggest a role for FOXO1 in the
pathobiology of BL. We screened 7 cell lines and 4 patient-derived
xenograft samples for FOXO1 mutations and identified 7 mutations
in 3 lines and 2 xenografts, including S22P in the endemic cell line
Jiyoye and D82N in the sporadic BL cell line Ramos (Figure 4A).
Both of these mutations were recurrent in the patient cohorts
(Figure 1). The expression of the mutant alleles carrying S22P and
S37W in Jiyoye, and D82N in Ramos was confirmed by Sanger
sequencing. Interestingly, all patient-derived xenograft samples and
cell lines showed strong nuclear retention of FOXO1, irrespective of
mutation status (Figure 4B).
Using CRISPR/Cas9 gene editing, we investigated the effect of
FOXO1 knockout in Jiyoye (S22P, S37W) and Ramos (D82N) cell
lines using 3 guide sequences (supplemental Figure 7). In Jiyoye,
FOXO1 editing with each of 3 single-guide RNAs caused almost
complete loss of FOXO1 protein expression in bulk cell cultures and
a significant decrease in cell proliferation compared with controls
(Figure 4C). The decrease in cell proliferation was confirmed by the
further investigation of multiple low-expressing, single-cell clones
that also showed no significant increase in apoptosis, albeit this
difference was not significant (Figure 4D; supplemental Figure 8). In
contrast, a decrease in cell proliferation in the Ramos line, was only
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Figure 2. Survival analysis. Kaplan-Meier plots showing association of FOXO1 mutations with overall survival in sporadic BL (A) and endemic BL (B) and DFS in sporadic
BL (C) and endemic BL (D).
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observed in the bulk population edited by sg3 and could not be
confirmed by analysis of individual clones (supplemental Figure 9).
Discussion
This study, utilizing a large cohort of pediatric BL patient samples,
reveals that FOXO1 mutations occur in both sporadic and endemic
BL at substantially higher frequency than previously reported.20-24
This is likely from the different technical approaches used because
coverage of FOXO1 on many NGS platforms is poor.17,39 We
observed that the most frequent FOXO1 mutations were located
within or immediately adjacent to the AKT recognition motif
(RxRxxS/T), as has previously been reported in DLBCL.17 However,
we also show for the first time that the hotspot mutations within the
AKT recognition motif differ between BL subtypes, with the T24
residuemost commonly affected in sporadic cases and S22 in endemic
cases. In contrast to DLBCL, we identified only a single sporadic BL
case with an M1 mutation, predicted to remove the AKT recognition
motif by forcing use of an alternate translation start site. Furthermore, we
identified mutations outside the AKT motif, predominantly in endemic
BL, but in contrast to DLBCL,17 these did not cluster within the DNA-
binding domain. The functional significance of these mutations, and
whether the differences observed between sporadic and endemic
BL represent differences in the regulation of FOXO1, or different
mutational pressures or processes, remain to be explored.
In almost all cases, the FOXO1 mutations were present within the
major tumor cell clone at initial diagnosis, supporting an important
biological role for mutant FOXO1 in the development of BL. In
concordance with our data, Grande et al have recently identified
FOXO1 missense mutations in both endemic and sporadic BL in
a high proportion of cases irrespective of tumor EBV status.40
FOXO1 mutations in DLBCL have been reported to be associated
with a poor prognosis and to be acquired or expanded at
relapse.17,39 In our study, we demonstrated persistence of FOXO1
mutation in paired presentation/relapse sample, consistent with
a role throughout the disease course, but there was no correlation
between FOXO1 mutations and clinical outcome in either sporadic
or endemic BL. This could represent differences in the biology or
treatment of DLBCL and BL, but the prognostic effect in DLBCL
has also more recently been challenged.18
We identified 2 genes that were more frequently mutated in cases
harboring FOXO1 mutations: the ATP-dependent RNA helicase
DDX3X (DEAD-Box Helicase 3 X-Linked) and ARID1A (AT-rich
interaction domain 1A), a member of the SWI/SNF chromatin-
remodeling complex. DDX3X and ARID1Amutations are commonly
found in BL and are frequently silencing events, such as nonsense
and frameshift mutations. The functional relevance of the FOXO1-
DDX3X/ARID1A association is, however, currently not clear. Notably,
it has previously been reported that mutations in the SWI/SNF family
members ARID1A and SMARCA4 are mutually exclusive.22 We did
not observe this in our study, with 4 cases harboring mutations in
both genes, suggesting that dysregulation of the SWI/SNF complex
is more complicated in BL than initially proposed.
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Figure 3. Overview of somatic mutations identified in the pediatric sporadic BL cohort. Mutations affecting genes previously identified as commonly mutated in BL
are shown. Each column represents a BL sample, ordered by the presence or absence of FOXO1 mutations. EBV status is indicated as positive or negative. Mutations are
colored-coded by type. The prevalence of different mutations in FOXO1 mutated (blue) and nonmutated (orange) cases is shown in the right-hand barcharts and genes
significantly more commonly mutated in FOXO1 mutated cases are indicated by an asterisk (Fisher’s exact test). EBV, Epstein-Barr virus; Fs, frameshift.
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BL cells are believed to be dependent on signaling through the PI3K
pathway.8,9 In physiological states, PI3K signaling drives AKT-
dependent phosphorylation of FOXO1 at 3 specific sites (T24,
S256, and S3196,17), resulting in binding to 14-3-3 and seques-
tration of FOXO1 in the cytoplasm.6,7 In apparent contradiction to
this, we found abundant FOXO1 in the nucleus of both human BL
cell lines and patient-derived xenograft samples, consistent with
transcriptional activity. Mutations affecting the N-terminal AKT
recognition motif, including those detected in this study, have been
shown to prevent FOXO1 cytoplasmic localization,17 and indeed
Kabrani et al have very recently demonstrated that T24 mutation
drives nuclear retention of FOXO1 and thereby cell proliferation and
survival in murine PI3K-driven, BL-like tumors carrying acquired
FOXO1 mutations.19 In our study, FOXO1 knockout resulted in
a significant decrease in cell proliferation in an endemic BL cell line,
supporting an oncogenic function for FOXO1 in human BL as well.
Thus, FOXO1 mutation likely represents 1 mechanism by which
active PI3K signaling and FOXO1 activity can cooccur in BL cells.
However, further complexities must exist in the control of FOXO1 in
BL as nuclear localization is seen even in the absence of AKT
recognition motif mutations. This lack of association between
FOXO1 mutation status and FOXO1 nuclear localization may
explain the lack of association with clinical outcome.
In conclusion, we have identified a previously undiscovered high
frequency of FOXO1 mutations in pediatric sporadic and endemic
BL. Together with previous findings that FOXO1 is a driver of in
DLBCL15,17 and murine BL-like tumors19 and may mediate therapeutic
resistance,41 our data further identify the transcription factor FOXO1
as an important factor in pathophysiology of several germinal
center–derived B-cell lymphomas. Further exploration of the
mechanisms uncoupling FOXO1 from PI3K signaling will aid
understanding of BL pathogenesis. With small molecule inhibitors
in development,42,43 FOXO1 may represent an emerging thera-
peutic target for a substantial proportion of pediatric BL patients at initial
diagnosis and for the currently hard-to-treat children with relapsed
disease in both high- and low-income countries.
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